May 18, 2020
Rutgers Researchers Receive Inaugural HealthAdvance™ Award To Develop First-in-Class Anti-Cancer Therapeutics
HealthAdvance™ announces its inaugural award to advance the commercialization of anti-cancer therapeutics being developed by researchers Raymond B. Birge from New Jersey Medical School and William Welsh from Robert Wood Johnson Medical School, in collaboration with Youyi Peng at the Rutgers Cancer Institute of New Jersey. HealthAdvance provides up to $200,000 for a two-year period to support the development and de-risking of early-stage life sciences technologies with an impact on human health.
October 29, 2019
Rutgers University Receives $4M as New Hub Under NIH REACH Program to Accelerate Development of Biomedical Technologies
Rutgers, The State University of New Jersey was selected as one of five new hubs under the National Institutes of Health’s Research Evaluation and Commercialization Hubs (REACH) program to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics, and tools to improve patient care, enhance health, and train the next generation of innovators.
New Ventures & Commercialization Funding Symposium Series: Road to Commercialization
March 18, 2021
9:00 a.m. to 11:45 a.m. EST
The first of three symposia presented by the New Ventures and Commercialization Funding team at Rutgers Office for Resarch, join keynote speaker Stephen Chang of Histogen and a panel of experts to learn the road to commercialization. Presenters will discuss best practices and effective strategies towards networking and communicating with industry experts as well as understanding what industry partners seek from academic partners.
Attending the symposium is required for applicants seeking TechAdvance or HealthAdvance funding as well as applicants who are in the review process/granted awards but have not completed this requirement.
The symposium, formerly known as TechAdvance 101 Boot Camp, is open to Rutgers students, postdocs, medical fellows, basic and clinical research staff, and faculty with an interest in applying for TechAdvance or HealthAdvance funding.
A Certificate of Participation will be provided to all attendees.
9:00 a.m. - Opening Remarks: Sherry Onweller, MBA, New Ventures and Commercialization Funding
9:05 a.m. - Keynote Presentation: Stephen Chang, PhD, Life Science Consultant, Board Member, Histogen
10:05 a.m. - Brief Presentations by:
- Tatiana Litvin-Vechnyak, PhD, Associate Vice President, Innovation Ventures, Rutgers Office for Research
- Eusebio Pires, PhD, MBA, Rutgers TechAdvance
- Pragati Sharma, PhD, Rutgers HealthAdvance
- Luis Ahn, MBA, New Ventures, Rutgers Office for Research
- Dan Benderly, MBA, Rutgers Site I-Corps
10:45 a.m. - Panel Discussions by:
- Chaoyang Xue, PhD, Associate Professor, Rutgers New Jersey Medical School, TechAdvance Awardee
- Kara Moore, MLS, Director, Corporate Intelligence and Assessment, Rutgers Corporate Engagement Center
- Lisa Lyu, PhD, Licensing Manager, Innovation Ventures, Rutgers Office for Research
11:40 a.m. - Closing Remarks: Aparna Jadhav, MS, Rutgers TechAdvance Intern